Medscape
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an exceptional circumstances positive opinion for Maapliv, a solution of amino acids intended for the treatment of maple syrup urine disease (MSUD) in patients presenting with an acute decompensation episode from birth and who are not eligible for …
Read More
EMA Recommends Treatment for Maple Syrup Urine Disease
Margarett Lanz
16:26
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an exceptional circumstances positive opinion for Maapliv, a solution of amino acids intended for the treatment of maple syrup urine disease (MSUD) in patients presenting with an acute decompensation episode from birth and who are not eligible for
